jRCT1030210229招募中不适用
Characteristics of patients with COPD newly treated with fluticasone/umeclidinium/vilanterol, budesonide/glycopyrronium/formoterol, or multiple inhaler triple therapy in the Medical Data Vision, Inc. clinical database
GlaxoSmithKline K.K.0 个研究点目标入组 3,500 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 3,500
- 主要终点
- Age at Index date
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 40age old over 至 No limit（—）
- 性别
- All
入选标准
- •At least one pharmacy prescription claim(s) for Trelegy, Breztri Aerosphere, or a MITT between 1 September 2019 and most recent data available at the time of the study. The index date will be earliest initiation of treatment. Specifically:
- •a. Date of first prescription for Trelegy
- •b. Date of first prescription for Breztri Aerosphere
- •c. Any of the following scenarios for MITT, occurring no earlier than the start of the study period:
- •i. Prescription date of the last monotherapy component (ICS, LAMA, or LABA) overlapping with both of two preceding monotherapies (ICS, LAMA, or LABA)
- •ii. Prescription date of last monotherapy component (LAMA or ICS) overlapping with preceding dual therapy (ICS/LABA or LAMA/LABA, respectively)
- •iii. Prescription date of the last dual therapy component (ICS/LABA or LAMA/LABA) added to preceding monotherapy (LAMA or ICS, respectively)
- •Age >=40 at index date
- •>=2 outpatient or >=1 hospitalization record with an International Classification of Diseases, 10th Revision (ICD-10) diagnosis code for COPD (J42, J43 or J44) in the 12 calendar months prior and including the index calendar month.
- •>=1 outpatient or hospitalization record with any ICD-10 diagnosis code in the 6-month period prior to the 12-month lookback period.
- •New users as of the index date. Defined as follows (not mutually exclusive):
- •a) No record of Trelegy in the 12-month lookback period (Objective 1a)
- •b) No record of triple therapy (Trelegy, Breztri Aerosphere, or MITT) in the 12-month lookback period (Objective 1b).
- •c) No record of any maintenance therapy (ICS, LABA, or LAMA-containing therapies) in the 12-month lookback period (Objective 2)
- •For Objectives 1b and 2, patients will be assigned to their respective study cohorts based on whether the index prescription record was for Trelegy, Breztri Aerosphere, or MITT.
排除标准
- •For the analysis under primary objective b, patients will be excluded if they used inhaled triple therapy (Trelegy, Breztri Aerosphere, or open inhaled triple treatment) in the 12-month lookback period
- •For the analysis under secondary objective, patients will be excluded if they used any maintenance therapy (ICS, LABA, or LAMA containing medications) in the 12-month lookback period
结局指标
主要结局
Age at Index date
Age of the patient at the index date
Calendar year of index date
Calendar year when the index date occurred
Quarter of index date
Quarter of the year when the index date occurred
Gender
Gender of the patient
Treatment history
History of treatments received by the patient
BMI
Body Mass Index of the patient
Smoking status
Smoking status of the patient
Presence of Lung function test
Indicates whether a lung function test was performed
Quan Charlson Comorbidity Index
Score quantifying the burden of comorbidities
History of COPD exacerbations requiring hospitalization
History of COPD exacerbations that required hospitalization
History of COPD exacerbations not requiring hospitalization
History of COPD exacerbations that did not require hospitalization
Comorbidities
Presence of other medical conditions alongside the primary condition
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Characteristics of patients with COPD newly treated with fluticasone/umeclidinium/vilanterol, budesonide/glycopyrronium/formoterol, or multiple inhaler triple therapy in the Medical Data Vision, Inc. clinical databaseCOPDJPRN-jRCT1030210229Akiyama Shoko3,500
招募中
不适用
Development of COPD patients cohortDiseases of th respiratory systemKCT0002129Asan Medical Center1,000
尚未招募
不适用
Characterisation of ambulatory COPD patients with long-term oxygen therapyJ44.8Other specified chronic obstructive pulmonary diseaseDRKS00027874ungenklinik Köln MerheimKliniken der Stadt KoelnUniversität Witten/Herdecke40
招募中
不适用
Safety of Tiotropium Prescription in Chronic Obstructive Pulmonary Disease (COPD): A survey in patients taking Tiotropium at the time of an admission to hospital with an Acute Exacerbation of COPD.Chronic Obstructive Pulmonary DiseaseRespiratory - Chronic obstructive pulmonary diseaseACTRN12615000492550Medical Research Institute of New Zealand100
已完成
不适用
Effect on Hospitalisation and Cost Effectiveness of a Respiratory Coordinated Care Program for patients with Chronic Obstructive Pulmonary Disease.COPDRespiratory - Chronic obstructive pulmonary diseasePublic Health - EpidemiologyACTRN12615001095550Respiratory Department St George Hospital100